OncoDNA SA, headquartered in Belgium, is a pioneering company in the field of precision medicine, specialising in oncology. Founded in 2014, OncoDNA has established itself as a leader in genomic profiling and personalised treatment solutions, focusing on improving patient outcomes in cancer care. The company offers a range of innovative products and services, including comprehensive genomic tests that provide critical insights into tumour characteristics, enabling tailored therapeutic strategies. OncoDNA's unique approach combines advanced bioinformatics with a robust database of clinical outcomes, setting it apart in the competitive landscape of cancer diagnostics. With a strong presence in Europe and expanding operations globally, OncoDNA has achieved significant milestones, including partnerships with leading healthcare institutions and recognition for its contributions to personalised medicine.
How does OncoDNA SA's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
OncoDNA SA's score of 26 is lower than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
OncoDNA SA, headquartered in Belgium, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and formal commitments suggests that OncoDNA SA may still be in the early stages of developing a comprehensive climate strategy. In the context of the biotechnology industry, many companies are increasingly focusing on sustainability and carbon footprint reduction. However, without specific initiatives or targets, OncoDNA SA's climate commitments remain unclear. As the industry evolves, it will be essential for OncoDNA SA to establish measurable goals and transparent reporting to align with global climate action efforts.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
OncoDNA SA has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

